TICKERNERD
Menu
LXEOLXEOHealthcare · Biotechnology

LXEO Stock Forecast: Lexeo Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 24 Aug 2026
$4.92
+0.82% on the day

The 9 Wall Street analysts covering Lexeo Therapeutics, Inc. hold a median 12-month price target of $20 — +306.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 31 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$403.7M
Ticker Nerd rank
31 / 100
Median analyst target
$20
Analysts covering
9
Revenue$0.0
Operating income−$22.3M
Net income−$20.2M
Free cash flow−$21.2M
Quarterly, 8 quarters to 31 Mar 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−1.2%
1M
+5.6%
YTD
−50.5%
1Y
+0.4%
From 52W high
−53.7%
From 52W low
+19.1%
$4
$11
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

LXEO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Lexeo Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
31 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
80
Momentum
58
Size
57
Issuance
41
Quality
40
Revisions
33
Accruals
31
Value
28
Volatility
20

Growth (80): Sales and profits are climbing, and climbing faster than before.

Volatility (20): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

LXEO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LXEO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15$20$25$30Oct 25Jan 26Apr 26Jul 26LXEOHigh $30Median $20Low $9

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says9 analysts
9 Buy0 Hold0 Sell
Low $9Median $20High $30

The green dot is the last close — the median target sits +306.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
25 June 2026JP MorganMaintainsOverweight$12 → $9.00
11 May 2026Chardan CapitalMaintainsBuy—
13 Jan 2026Chardan CapitalMaintainsBuy—
13 Jan 2026HC Wainwright & Co.MaintainsBuy—
18 Dec 2025Raymond JamesInitiatesStrong Buy—
11 Dec 2025Chardan CapitalMaintainsBuy—
1 Dec 2025Cantor FitzgeraldInitiatesOverweight—
20 Nov 2025Cantor FitzgeraldInitiatesOverweight—
6 Nov 2025Chardan CapitalMaintainsBuy—
5 Nov 2025Chardan CapitalMaintainsBuy$17
21 Oct 2025HC Wainwright & Co.MaintainsBuy—
15 Oct 2025GuggenheimInitiatesBuy—
7 Oct 2025Chardan CapitalMaintainsBuy—
7 Oct 2025HC Wainwright & Co.MaintainsBuy—
7 Oct 2025Leerink PartnersMaintainsOutperform—
15 Aug 2025Chardan CapitalMaintainsBuy—
15 Aug 2025HC Wainwright & Co.MaintainsBuy—
15 Aug 2025Leerink PartnersMaintainsOutperform—
31 July 2025OppenheimerInitiatesOutperform—
30 May 2025JP MorganMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LXEO appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

LXEO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 24 Aug 2026, Lexeo Therapeutics, Inc. returned +0.4% against +19.6% for the S&P 500, dividends included.

LXEO vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200Oct 25Jan 26Apr 26Jul 26LXEOS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

LXEO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Lexeo Therapeutics, Inc. (LXEO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.6×

Cheaper than 86% of US stocks

Price / sales
—
Price / book
1.6×

Cheaper than 55% of US stocks

EV / EBITDA
−2.1×

Cheaper than 71% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−46.8%

Higher than 22% of US stocks

Return on assets
−27.6%

Higher than 15% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Lexeo Therapeutics, Inc. (LXEO) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Lexeo Therapeutics, Inc. has a market value of $403.7M and an enterprise value of $195.5M.

  • Revenue in the twelve months to 31 Mar 2026: $0.0.

  • Net income over the same four quarters: −$87.5M.

  • Diluted earnings per share, trailing twelve months: $−1.45.

  • Free cash flow in the twelve months to 31 Mar 2026: −$98.4M, after $432K of capital spending.

  • Shares outstanding: 74.1M.

  • Trailing P/E: −2.6×; forward P/E: −3.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Lexeo Therapeutics, Inc. employs 63 people.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 25 Aug 2026

Data provided by Twelve Data

Peers

LXEO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
LXEOLexeo Therapeutics, Inc.$403.7M
31
ARCTArcturus Therapeutics Holdings, Inc.$382.1M
61
UPBUpstream Bio, Inc.$381.8M
31
LYELLyell Immunopharma, Inc.$380.6M
65
RCKTRocket Pharmaceuticals, Inc.$379.9M
52
ENTAEnanta Pharmaceuticals, Inc.$388.6M
87
IPSCCentury Therapeutics, Inc.$371.9M
39

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Lexeo Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest LXEO news & analysis

Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights

GlobeNewsWire · 12 Aug 2026positive

Lexeo Therapeutics reported second quarter 2026 financial results and operational highlights, including the finalized SUNRISE-FA 2 pivotal trial protocol and first patient enrollment for LX2006 in Friedreich ataxia cardiomyopathy, with topline data expected in the second half of 2027. The company also noted FDA RMAT designation for LX2020 in PKP2-ACM, continued CLARITY-FA enrollment, and cash reserves of $234.2 million expected to fund operations into 2028.

Why it matters — The initiation of the pivotal SUNRISE-FA 2 trial for LX2006 and the RMAT designation for LX2020 mark key clinical milestones for Lexeo's cardiovascular gene therapy pipeline, while its cash runway into 2028 supports these programs.

Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathy

GlobeNewsWire · 5 Aug 2026positive

The FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to Lexeo Therapeutics' investigational therapy LX2020 for the treatment of PKP2 arrhythmogenic cardiomyopathy. The designation was based on recent interim clinical data from the ongoing Phase I/II clinical trial evaluating LX2020 for PKP2-ACM.

Why it matters — LXEO watchers would care because the RMAT designation marks regulatory progress for LX2020, a key pipeline candidate in development for PKP2 arrhythmogenic cardiomyopathy.

FAQ

Frequently asked questions about LXEO stock

What is the LXEO stock price forecast for 2026-2027?

The 9 Wall Street analysts covering Lexeo Therapeutics, Inc. have a median 12-month price target of $20, with estimates ranging from $9 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is LXEO stock a buy right now?

Of the 9 analysts covering Lexeo Therapeutics, Inc., 9 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Lexeo Therapeutics, Inc. 31 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank LXEO?

As at 22 Aug 2026, Lexeo Therapeutics, Inc. ranks 31 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (80 of 100).

Will LXEO stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies +306.5% from the last close, and Ticker Nerd's factor model ranks Lexeo Therapeutics, Inc. 31 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the LXEO stock forecast for 2030?

No analyst covering Lexeo Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LXEO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9 to $30 over the next 12 months.

How has LXEO stock performed over the past year?

Lexeo Therapeutics, Inc. returned +0.4% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Lexeo Therapeutics, Inc. do?

Lexeo Therapeutics Inc. is a biotechnology company that focuses on the development and commercialization of innovative genetic therapies for complex diseases.

What is the latest news on LXEO?

The most recent item we track (GlobeNewsWire, 12 Aug 2026): "Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights". Lexeo Therapeutics reported second quarter 2026 financial results and operational highlights, including the finalized SUNRISE-FA 2 pivotal trial protocol and first patient enrollment for LX2006 in Friedreich ataxia cardiomyopathy, with topline data expected in the second half of 2027. The company also noted FDA RMAT designation for LX2020 in PKP2-ACM, continued CLARITY-FA enrollment, and cash reserves of $234.2 million expected to fund operations into 2028.

Company

About Lexeo Therapeutics, Inc.

Lexeo Therapeutics Inc. is a biotechnology company that focuses on the development and commercialization of innovative genetic therapies for complex diseases. Established with a mission to transform lives through groundbreaking advancements, Lexeo Therapeutics is primarily engaged in addressing genetic disorders that have limited treatment options. The company emphasizes its work in the fields of cardiology, ophthalmology, and neurodegenerative diseases, placing a strong focus on precision medicine to deliver targeted therapeutic solutions. Lexeo Therapeutics holds a distinct position in the biotechnology industry by leveraging advanced technologies in gene therapy to pioneer treatments that aim to correct or replace defective genes at the root cause of diseases. This approach has significant implications not only for patient outcomes but also for expanding the horizons of genetic medicine. In the financial market, Lexeo Therapeutics Inc. is recognized for its potential to contribute to the advancement of healthcare solutions, playing a crucial role in the ongoing evolution of biopharmaceutical innovation and development.

CEO Mr. R. Nolan Townsend M.B.A. · 63 employees · United States · https://www.lexeotx.com